BPMC logo

Blueprint Medicines (BPMC) Company Overview

Profile

Full Name:

Blueprint Medicines Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 30, 2015

Indexes:

Not included

Description:

Blueprint Medicines Corporation is a precision therapy company specializing in genomic cancer diseases, rare diseases, and cancer immunotherapy. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines Corporation is developing the following drugs: avapritinib - for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263 - an oral potent inhibitor for the treatment of indolent SM and other mast cell diseases; fisogatinib - an oral potent inhibitor currently in phase I clinical trials for the treatment of hepatocellular carcinoma and other drugs for the treatment of rare genomic and tumor diseases.

Key Details

Price

$94.35

Annual Revenue

$508.82 M(+104.04% YoY)

Annual EPS

-$1.07(+87.22% YoY)

Annual ROE

-31.26%

Beta

1.24

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 13, 2025

Recent annual earnings:

Feb 13, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 14, 25 Needham
Buy
Feb 14, 25 JMP Securities
Market Outperform
Feb 14, 25 HC Wainwright & Co.
Buy
Feb 13, 25 Needham
Buy
Feb 4, 25 JP Morgan
Overweight
Jan 27, 25 Piper Sandler
Neutral
Jan 15, 25 JMP Securities
Market Outperform
Jan 13, 25 Wedbush
Outperform
Jan 13, 25 Needham
Buy
Jan 2, 25 Stephens & Co.
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Blueprint Medicines?
  • Does Blueprint Medicines pay dividends?
  • What sector is Blueprint Medicines in?
  • What industry is Blueprint Medicines in?
  • What country is Blueprint Medicines based in?
  • When did Blueprint Medicines go public?
  • Is Blueprint Medicines in the S&P 500?
  • Is Blueprint Medicines in the NASDAQ 100?
  • Is Blueprint Medicines in the Dow Jones?
  • When was Blueprint Medicines's last earnings report?
  • When does Blueprint Medicines report earnings?
  • Should I buy Blueprint Medicines stock now?

What is the ticker symbol for Blueprint Medicines?

The ticker symbol for Blueprint Medicines is NASDAQ:BPMC

Does Blueprint Medicines pay dividends?

No, Blueprint Medicines does not pay dividends

What sector is Blueprint Medicines in?

Blueprint Medicines is in the Healthcare sector

What industry is Blueprint Medicines in?

Blueprint Medicines is in the Biotechnology industry

What country is Blueprint Medicines based in?

Blueprint Medicines is headquartered in United States

When did Blueprint Medicines go public?

Blueprint Medicines's initial public offering (IPO) was on April 30, 2015

Is Blueprint Medicines in the S&P 500?

No, Blueprint Medicines is not included in the S&P 500 index

Is Blueprint Medicines in the NASDAQ 100?

No, Blueprint Medicines is not included in the NASDAQ 100 index

Is Blueprint Medicines in the Dow Jones?

No, Blueprint Medicines is not included in the Dow Jones index

When was Blueprint Medicines's last earnings report?

Blueprint Medicines's most recent earnings report was on Feb 13, 2025

When does Blueprint Medicines report earnings?

The next expected earnings date for Blueprint Medicines is May 2, 2025

Should I buy Blueprint Medicines stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions